FindTrial
Sign In

CXA-10

DRUG9 trials

Sponsors

Complexa, Inc., Sally E. Wenzel MD, University of Colorado, Denver, Gladwin, Mark, MD

Conditions

Acute Kidney InjuryAcute Kidney Injury (Nontraumatic)AsthmaChronic Kidney InjuryObesityPAHPrimary Focal Segmental GlomerulosclerosisPulmonary Arterial Hypertension

Phase 1

Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
CompletedNCT02248051
Complexa, Inc.Acute Kidney Injury (Nontraumatic)
Start: 2014-09-30End: 2015-09-30Updated: 2018-02-01
Oral CXA-10 Study in Healthy Volunteers
CompletedNCT02313064
Complexa, Inc.Chronic Kidney Injury
Start: 2015-01-31End: 2015-06-30Updated: 2016-05-03
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
CompletedNCT02460146
Complexa, Inc.Acute Kidney Injury
Start: 2015-04-30End: 2015-10-31Updated: 2016-05-03
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
CompletedNCT02547402
Complexa, Inc.Acute Kidney Injury
Start: 2015-12-31End: 2016-02-29Updated: 2016-05-03

Phase 2

FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
CompletedNCT03422510
Complexa, Inc.Primary Focal Segmental Glomerulosclerosis
Start: 2018-04-15End: 2020-07-31Updated: 2020-08-03
Anti-Inflammatory Lipid Mediators in Asthma
WithdrawnNCT03680976
Sally E. Wenzel MDAsthma
End: 2021-04-30Updated: 2018-09-21
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
RecruitingNCT03762395
University of Colorado, DenverAsthma, Obesity
Start: 2023-02-08End: 2030-01-30Target: 60Updated: 2025-06-10
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
TerminatedNCT04053543
Complexa, Inc.PAH
Start: 2019-08-09End: 2020-08-12Updated: 2020-08-26
Oral CXA-10 in Pulmonary Arterial Hypertension
TerminatedNCT04125745
Gladwin, Mark, MDPulmonary Arterial Hypertension
Start: 2019-10-31End: 2020-12-01Updated: 2022-01-12